Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The company announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand prog...
The availability of Micro-Neighborhood® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of...
RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:OPRX) with a Outperform and lowers the price target from $17 to ...
Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $15...
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.06) by...
JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 pr...
